Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
At present, a variety of antithrombotic regimens are prescribed in the early postprocedure
period after transcatheter aortic valve implantation (TAVI). Dual antiplatelet therapy (DAPT)
using aspirin and a thienopyridine in the initial period after TAVI is the recommended
strategy; however, mono antiplatelet therapy using aspirin is suggested not to be inferior.
In patients with atrial fibrillation (AF) or another indication for oral anticoagulation
(OAC), no recommendations on best treatment regimen currently exist although triple therapy
(OAC + DAPT) is best avoided due to increased bleeding risk.
We hypothesise that the omission of clopidogrel in the first 3 months after TAVI is safer and
not less beneficial than the addition of clopidogrel to aspirin (cohort A) or OAC (cohort B).